NAU-10-0036(20902)

Neurourology and Urodynamics 26:1–2 (2010)

LETTER TO THE EDITOR

A[Q1] Basis for Long-Term Midurethral Tape Complications

The complications reported[1] may be but a prelude to many such reports in the future, a conclusion reached on revisiting the original studies which led to the creation of this operation.

Immunological reaction—a fundamental problem of all implants. Individuals react differently to implanted tapes. In the first animal experiments conducted at Royal Perth Hospital in 1987 and 1989,[2] we were surprised at the range of host reaction to the implanted tapes. In some animals, there was rapid and total integration of tape into the tissues. In others, there was a chronic foreign body reaction characterized by granulation tissue. However, even with discharge and sinuses, the animals remained well, with normal temperatures, and low inflammatory changes on testing with radioactive gallium studies.[2] Bacteriological testing rarely revealed any growth. The first group of patients had similar histological, bacteriological, and clinical patterns.[2,3] As all the factors in the operations were identical, it can be deduced from this data, that the *incidence* of a foreign body reaction is largely immunologically determined.

Tape slippage as a cause of tape erosion. In the first 24 hr, the tape becomes surrounded by fluid containing polymorphonuclear leucocytes and macrophages. A heavier implant causes a larger wound reaction, and so is more likely to slip and erode. In an RCT, Sivaslioglu demonstrated a 13.7% erosion rate with an unbuttressed IVS tape, and a 1.8% erosion rate when the tape was buttressed by approximating the underlying vaginal fascia.[4] He concluded that it was important to buttress a "tension-free" tape so as to prevent slippage, and therefore, erosion.

Stretching and narrowing of the tape as a cause of transection. The origin of the term "tension-free" was first used in 1994, and signified placement of a non-stretch Mersilene tape against the posterior wall of urethra without indentation ("tension-free"). An elastic tape such as the TVT easily narrows on stretching, a major factor in urethral erosion and transection. However, this does not explain why the constriction occurred years afterwards.

A collagenous neoligament contracts with time.[5] The origin of the midurethral sling can be traced to a simple clinical test, a "simulated operation." Pressing a hemostat upwards on the vagina exactly at the midurethra, controlled urine loss on coughing, and restored urethrovesical geometry,[6] emphasizing the importance of a competent pubourethral ligament. We reasoned that it was impossible to repair a structure composed largely of smooth muscle by suturing it. This fact caused us to use the collagenous tissue reaction to foreign body implantation to a positive effect, to create a collagenous pubourethral neoligament.[2]

The relative proportion of the various glycosaminoglycans influences the mechanical properties of the tissue.[7] During pregnancy, there is a marked change in the ratio of hyaluronic acid to dermatan sulfate, resulting in marked distensibility of collagen.[7] Conversely, the increased content of dermatan sulfate with age, Thonar and Kuettner[8] renders the tissue less distensile.

This shrinkage in collagen with age confirms Jones et al.'s advice,[1] that setting the tape more tightly in patients with intrinsic sphincter defect is not only inadvisable, but potentially hazardous in the longer term.

The type of mesh. The TVT tape is cut from a large diamond patterned mesh. Following implantation, the polypropylene fibrils forming each diamond become surrounded by type 1 collagen which shrinks with age, causing the relatively thick, 150 μm fibrils to gradually cut into the substance of the urethra, much like a wire cheese knife. A tape already tight immediately after operation[1] would predispose to this complication. Nor is a fascial sling immune from longer term collagen constriction. I have seen a patient presenting with acute retention 25 years after an Aldridge sling operation. Excision of a 1 cm segment per vaginam restored micturition without loss of continence.

Conclusions and future directions. In a general sense, we need to examine all implants from the viewpoint of mechanical properties of the mesh, and the immunological reaction of a particular patient.

(1) Any suburethral tape should be non-stretch and preferably, knitted from lighter weight threads.
(2) If the tape is non-stretch, it should touch, but not indent the urethra.
(3) If the tape is elastic, it is mandatory to leave a space, so as to allow for post-operative elastic retraction.
(4) In patients who cannot pass any urine for some days, post-operative loosening of the tape is preferable to self-catheterization.
(5) Suburethral plication of the underlying vaginal fascia reduces slippage and erosion, and it requires only one extra suture.
(6) Patients have different immunology, and foreign body reactions will inevitably occur in some patients, sometimes many years after implantation. This has to be explained in detail during the consent process.

Re Risk of tape-related complications after TVT is at least 4%, Jones R. et al. Neurourol. and Urodynamics 29:40–41 (2010).
Christopher Chapple led the review process.
*Correspondence to: Prof. Peter Petros, MB BS (Syd), Ph.D. (Uppsala), DS (UWA), M.D. (Syd), FRCOG (Lond), FRANZCOG CU, Wellington St. Perth, WA, Perth, Western Australia 6000, Australia. E-mail: kvinno@highway1.com.au
Received 28 January 2010; Accepted 29 January 2010
Published online in Wiley InterScience
(www.interscience.wiley.com)
DOI 10.1002/nau.20902

REFERENCES

1. Jones R, Abrams P, Hilton P, et al. Risk of tape-related complications after TVT is at least 4%. Neurourol Urodyn 2010;29:40–1.
2. Petros PE, Ulmsten U, Papadimitriou J. The autogenic neoligament procedure: a technique for planned formation of an artificial neo-ligament. Acta Obstet Gynecol Scand 1990;69:43–51.
3. Petros PE. "Development of the Intravaginal Slingplasty and other ambulatory vaginal operations" Doctor of Surgery Thesis, University of Western Australia, 1999.
4. Sivaslioglu AA, Unlubilgin E, Dölen E. The[Q4] multifilament polypropylene tape erosion trouble: tape structure vs surgical technique. Which one is the cause? Int Urogynecol J published online.
5. Peacock EE. Structure[Q5], synthesis and interaction of fibrous protein and matrix. Wound Repair. 3rd edition, Publishers WB Saunders Co; Philadelphia: 1984. pp. 56–101.
6. Petros PE, Von Konsky B. Anchoring the midurethra restores bladder neck anatomy and continence. Lancet 1999;354:997–8.
7. Downing SJ, Sherwood OD. The[Q6] physiological role of relaxin in the pregnant rat 1. The influence of relaxin on cervical collagen and glycosaminoglycans. 1986;118:471–9.
8. Thonar EJMA, Kuettner KE. Biochemical basis of age related changes in proteoglycans. In: Wight TN, Mecham RP, editors. Biology[Q7] of protoeglycans. Academic Press, Inc.; 1987. pp. 211–46.

Peter Petros MB BS (Syd),Ph.D. (Uppsala),
DS (UWA), M.D. (Syd), FRCOG (Lond), FRANZCOG CU
Perth, Western Australia[Q8], *Australia*

Q1: Please provide the conflict of interest details.

Q2: Please provide the complete affiliation details.

Q3: Please provide the conflict of interest details.

Q4: Please update.

Q5: The references 4 and 5 are not in sequential order hence it has been changed.

Q6: Please provide the journal title.

Q7: Please provide the publisher location.

Q8: Please provide the complete affiliation details.

WILEY
Publishers Since 1807

111 River Street, MS 8-02 Hoboken, NJ 07030-5774 USA

*****IMMEDIATE RESPONSE REQUIRED*****
Please follow these instructions to avoid delay of publication.

☐ **READ PROOFS CAREFULLY**
- This will be your only chance to review these proofs.
- Please note that the volume and page numbers shown on the proofs are for position only.

☐ **ANSWER ALL QUERIES ON PROOFS** (Queries for you to answer are attached as the last page of your proof.)
- Mark all corrections directly on the proofs. Note that excessive author alterations may ultimately result in delay of publication and extra costs may be charged to you.

☐ **CHECK FIGURES AND TABLES CAREFULLY**
- Check size, numbering, and orientation of figures.
- All images in the PDF are downsampled (reduced to lower resolution and file size) to facilitate Internet delivery. These images will appear at higher resolution and sharpness in the printed article.
- Review figure legends to ensure that they are complete.
- Check all tables. Review layout, title, and footnotes.

☐ **COMPLETE REPRINT ORDER FORM**
- Fill out the attached reprint order form. It is important to return the form even if you are not ordering reprints. You may, if you wish, pay for the reprints with a credit card. Reprints will be mailed only after your article appears in print. This is the most opportune time to order reprints. If you wait until after your article comes off press, the reprints will be considerably more expensive.

☐ **COMPLETE DISCLOSURE STATEMENT**
- It is essential that this form be completed and returned in order to proceed with publication.

☐ **ADDITIONAL COPIES**
- If you wish to purchase additional copies of the journal in which your article appears, please contact Jill Gottlieb at (201) 748-8839, fax (201) 748-6021, or E-mail at jgottlieb@wiley.com

☐ **COLOR CHARGE FORM**
- Fill out the attached color charge form even if you do not have color figures.
  Please indicate if you want to pay for color in print or color online only at no charge.

RETURN
- ☐ **PROOFS**
- ☐ **REPRINT ORDER FORM**
- ☐ **DISCLOSURE STATEMENT**
- ☐ **CTA (If you have not already signed one)**
- ☐ **COLOR CHARGE FORM**

RETURN WITHIN 48 HOURS OF RECEIPT TO Sarah Whalen at swhalen@wiley.com

QUESTIONS?

Sarah Whalen, Production Editor
Phone: (201) 748-8818
E-mail: swhalen@wiley.com
Refer to journal acronym (NAU) and article production number

C1

REPRINT BILLING DEPARTMENT · 111 River Street, MS 8-02 Hoboken, NJ 07030-5774 USA
E-MAIL: swhalen@wiley.com

PREPUBLICATION REPRINT ORDER FORM

Please complete this form even if you are not ordering reprints. This form **MUST** be returned with your corrected proofs and original manuscript. Your reprints will be shipped approximately 4 weeks after publication. Reprints ordered after printing will be substantially more expensive.

JOURNAL **Neurourology and Urodynamics (NAU)** VOLUME _____ ISSUE _____
TITLE OF MANUSCRIPT _____
MS. NO. _____ NO. OF PAGES _____ AUTHOR(S) _____

No. of Pages	100 Reprints	200 Reprints	300 Reprints	400 Reprints	500 Reprints
	$	$	$	$	$
1-4	**336**	**501**	**694**	**890**	**1052**
5-8	**469**	**703**	**987**	**1251**	**1477**
9-12	**594**	**923**	**1234**	**1565**	**1850**
13-16	**714**	**1156**	**1527**	**1901**	**2273**
17-20	**794**	**1340**	**1775**	**2212**	**2648**
21-24	**911**	**1529**	**2031**	**2536**	**3037**
25-28	**1004**	**1707**	**2267**	**2828**	**3388**
29-32	**1108**	**1894**	**2515**	**3135**	**3755**
33-36	**1219**	**2092**	**2773**	**3456**	**4143**
37-40	**1329**	**2290**	**3033**	**3776**	**4528**

**REPRINTS ARE ONLY AVAILABLE IN LOTS OF 100. IF YOU WISH TO ORDER MORE THAN 500 REPRINTS, PLEASE CONTACT OUR REPRINTS DEPARTMENT AT (201) 748-8873 FOR A PRICE QUOTE.

☐ Please send me _____ reprints of the above article at $ _____

Please add appropriate State and Local Tax for United States orders only. (Tax Exempt No._____) $ _____

Please add 5% Postage and Handling $ _____

TOTAL AMOUNT OF ORDER** $ _____

***International orders must be paid in currency and drawn on a U.S. bank*

Please check one: ☐ Check enclosed ☐ Bill me ☐ Credit Card
If credit card order, charge to: ☐ American Express ☐ Visa ☐ MasterCard

Credit Card No _____ Signature _____ Exp. Date _____

BILL TO:
Name _____
Institution _____
Address _____

SHIP TO: (Please, no P.O. Box numbers)
Name _____
Institution _____
Address _____

Purchase Order No. _____ Phone _____ Fax _____

E-mail _____

Neurourology And Urodynamics (NU) Disclosure Statement

Neurology And Urodynamics **wishes to ensure independence, objectivity, scientific rigor and a fair balance of representation, in all its activities. In order to ensure this, individuals participating in these activities are expected to disclose their financial or in-kind relationships with for-profit health industry entities that develop, manufacture, distribute or sell health care materials or services. Such relationships exclude personal or family medical care. NU recognizes that these relationships do not necessarily imply bias or decrease the value of participation in professional activities. Disclosure of these relationships is necessary for others to make an informed decision about the impact of the disclosed relationship. In addition, certain disclosures will require management, such as refusal from the review process.**

Each NU author, reviewer and editor is requested to complete this form. All relationships over the previous two calendar years and the current year (including future commitments which are foreseen over the coming year) must be disclosed. Lead authors must also provide a written statement specifying what they believe to be the most relevant conflicts of interest to their paper. If in doubt, reviewers should seek guidance from the editor who has contacted them as to whether they should proceed with a review. Editors with a COI will be excluded from supervising the review process.

First Name:

Last Name:

I, the undersigned do not have any existing or known future financial relationships or commercial affiliations to disclose:

Signed:

Date:

I, the undersigned have the following existing or known future financial relationships or commercial affiliations to disclose

Signed:

Dated:

Use the following list to declare your existing or known future financial relationships or commercial affiliations. Mark a cross in the appropriate box and indicate the name of the company.

1. Equity interests (or entitlement to same) of stocks, stock options, royalties, etc, including income from patents or copyrights
2. Service as a director or employment by a commercial organisation, whether or not remuneration is provided for such service
3. Sole ownership, partnership, or principal of a commercial enterprise
4. Ownership of patent(s)
5. Receipt of royalties
6. Consultant to company including positions on medical or scientific advisory boards
7. Honoraria for speaking at company sponsored meetings or events.
8. Participation in clinical trials
9. Support in the form of fellowships, travel grants, gifts, in-kind donations, etc.
10. Research grants, partial or full salary support from a commercial organisation for self or employees for whom you are managerially responsible (i.e. laboratory technical/research fellow for whom you are managerially responsible).
11. Any other type of financial or other relationship

	Company Name	Company Name	Company Name	Company Name	Company Name	Company Name	Company Name
1. Equity interests							
2. Director or employee							
3. Owner							
4. Owner of patent(s)							
5. Royalties							
6. Consultant							
7. Speaker Honorarium							
8. Trial participation							
9. Fellowship, travel grants							
10.Research grant							
11. Other – please indicate							

Lead Author's Statement on most relevant Conflict of Interest:

COPYRIGHT TRANSFER AGREEMENT

WILEY-BLACKWELL

Date: _____ Contributor name: _____

Contributor address: _____

Manuscript number (Editorial office only): _____

Re: Manuscript entitled _____

_____ (the "Contribution")

for publication in _____ (the "Journal")

published by _____ ("Wiley-Blackwell").

Dear Contributor(s):
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable Wiley-Blackwell to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement signed and returned as directed in the Journal's instructions for authors as soon as possible. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

1. The Contributor assigns to Wiley-Blackwell, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

2. Reproduction, posting, transmission or other distribution or use of the final Contribution in whole or in part in any medium by the Contributor as permitted by this Agreement requires a citation to the Journal and an appropriate credit to Wiley-Blackwell as Publisher, and/or the Society if applicable, suitable in form and content as follows: (Title of Article, Author, Journal Title and Volume/Issue, Copyright © [year], copyright owner as specified in the Journal). Links to the final article on Wiley-Blackwell's website are encouraged where appropriate.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's Employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution.

C. PERMITTED USES BY CONTRIBUTOR

1. Submitted Version. Wiley-Blackwell licenses back the following rights to the Contributor in the version of the Contribution as originally submitted for publication:

a. After publication of the final article, the right to self-archive on the Contributor's personal website or in the Contributor's institution's/employer's institutional repository or archive. This right extends to both intranets and the Internet. The Contributor may not update the submission version or replace it with the published Contribution. The version posted must contain a legend as follows: This is the pre-peer reviewed version of the following article: FULL CITE, which has been published in final form at [Link to final article].

b. The right to transmit, print and share copies with colleagues.

2. Accepted Version. Re-use of the accepted and peer-reviewed (but not final) version of the Contribution shall be by separate agreement with Wiley-Blackwell. Wiley-Blackwell has agreements with certain funding agencies governing reuse of this version. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement. NIH grantees should check the box at the bottom of this document.

3. Final Published Version. Wiley-Blackwell hereby licenses back to the Contributor the following rights with respect to the final published version of the Contribution:

a. Copies for colleagues. The personal right of the Contributor only to send or transmit individual copies of the final published version in any format to colleagues upon their specific request provided no fee is charged, and further-provided that there is no systematic distribution of the Contribution, e.g. posting on a listserve, website or automated delivery.

b. Re-use in other publications. The right to re-use the final Contribution or parts thereof for any publication authored or edited by the Contributor (excluding journal articles) where such re-used material constitutes less than half of the total material in such publication. In such case, any modifications should be accurately noted.

c. Teaching duties. The right to include the Contribution in teaching or training duties at the Contributor's institution/place of employment including in course packs, e-reserves, presentation at professional conferences, in-house training, or distance learning. The Contribution may not be used in seminars outside of normal teaching obligations (e.g. commercial seminars). Electronic posting of the final published version in connection with teaching/training at the Contributor's institution/place of employment is permitted subject to the implementation of reasonable access control mechanisms, such as user name and password. Posting the final published version on the open Internet is not permitted.

d. Oral presentations. The right to make oral presentations based on the Contribution.

4. Article Abstracts, Figures, Tables, Data Sets, Artwork and Selected Text (up to 250 words).

a. Contributors may re-use unmodified abstracts for any non-commercial purpose. For on-line uses of the abstracts, Wiley-Blackwell encourages but does not require linking back to the final published versions.

b. Contributors may re-use figures, tables, data sets, artwork, and selected text up to 250 words from their Contributions, provided the following conditions are met:

(i) Full and accurate credit must be given to the Contribution.
(ii) Modifications to the figures, tables and data must be noted. Otherwise, no changes may be made.
(iii) The reuse may not be made for direct commercial purposes, or for financial consideration to the Contributor.
(iv) Nothing herein shall permit dual publication in violation of journal ethical practices.

D. CONTRIBUTIONS OWNED BY EMPLOYER

1. If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/employer which must sign this Agreement (in addition to the Contributor's signature) in the space provided below. In such case, the company/employer hereby assigns to Wiley-Blackwell, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in paragraph A above.

2. In addition to the rights specified as retained in paragraph B above and the rights granted back to the Contributor pursuant to paragraph C above, Wiley-Blackwell hereby grants back, without charge, to such company/employer, its subsidiaries and divisions, the right to make copies of and distribute the final published Contribution internally in print format or electronically on the Company's internal network. Copies so used may not be resold or distributed externally. However the company/employer may include information and text from the Contribution as part of an information package included with software or other products offered for sale or license or included in patent applications. Posting of the final published Contribution by the institution on a public access website may only be done with Wiley-Blackwell's written permission, and payment of any applicable fee(s). Also, upon payment of Wiley-Blackwell's reprint fee, the institution may distribute print copies of the published Contribution externally.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end)

F. COPYRIGHT NOTICE

The Contributor and the company/employer agree that any and all copies of the final published version of the Contribution or any part thereof distributed or posted by them in print or electronic format as permitted herein will include the notice of copyright as stipulated in the Journal and a full citation to the Journal as published by Wiley-Blackwell.

G. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. If the Contribution was prepared jointly, the Contributor agrees to inform the co-Contributors of the terms of this Agreement and to obtain their signature to this Agreement or their written permission to sign on their behalf. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in Wiley-Blackwell's permissions form or in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury.

CHECK ONE BOX:

☐ Contributor-owned work

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

Contributor's signature _____ Date _____

Type or print name and title _____

Co-contributor's signature _____ Date _____

Type or print name and title _____

☐ Company/Institution-owned work (made-for-hire in the course of employment)

Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

☐ U.S. Government work

Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work," and is in the public domain in the United States. In such case, the employee may cross out Paragraph A.1 but must sign (in the Contributor's signature line) and return this Agreement. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

☐ U.K. Government work (Crown Copyright)

Note to U.K. Government Employees
The rights in a Contribution prepared by an employee of a U.K. government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. U.K. government authors should submit a signed declaration form together with this Agreement. The form can be obtained via http://www.opsi.gov.uk/advice/crown-copyright/copyright-guidance/publication-of-articles-written-by-ministers-and-civil-servants.htm

☐ Other Government work

Note to Non-U.S., Non-U.K. Government Employees
If your status as a government employee legally prevents you from signing this Agreement, please contact the editorial office.

☐ NIH Grantees

Note to NIH Grantees
Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of Contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate.

Softproofing for advanced Adobe Acrobat Users - NOTES tool

NOTE: ACROBAT READER FROM THE INTERNET DOES NOT CONTAIN THE NOTES TOOL USED IN THIS PROCEDURE.

Acrobat annotation tools can be very useful for indicating changes to the PDF proof of your article. By using Acrobat annotation tools, a full digital pathway can be maintained for your page proofs.

The NOTES annotation tool can be used with either Adobe Acrobat 4.0, 5.0 or 6.0. Other annotation tools are also available in Acrobat 4.0, but this instruction sheet will concentrate on how to use the NOTES tool. Acrobat Reader, the free Internet download software from Adobe, DOES NOT contain the NOTES tool. In order to softproof using the NOTES tool you must have the full software suite Adobe Acrobat 4.0, 5.0 or 6.0 installed on your computer.

Steps for Softproofing using Adobe Acrobat NOTES tool:

1. Open the PDF page proof of your article using either Adobe Acrobat 4.0, 5.0 or 6.0. Proof your article on-screen or print a copy for markup of changes.

2. Go to File/Preferences/Annotations (in Acrobat 4.0) or Document/Add a Comment (in Acrobat 6.0 and enter your name into the “default user” or “author” field. Also, set the font size at 9 or 10 point.

3. When you have decided on the corrections to your article, select the NOTES tool from the Acrobat toolbox and click in the margin next to the text to be changed.

4. Enter your corrections into the NOTES text box window. Be sure to clearly indicate where the correction is to be placed and what text it will effect. If necessary to avoid confusion, you can use your TEXT SELECTION tool to copy the text to be corrected and paste it into the NOTES text box window. At this point, you can type the corrections directly into the NOTES text box window. **DO NOT correct the text by typing directly on the PDF page.**

5. Go through your entire article using the NOTES tool as described in Step 4.

6. When you have completed the corrections to your article, go to File/Export/Annotations (in Acrobat 4.0) or Document/Add a Comment (in Acrobat 6.0).

7. **When closing your article PDF be sure NOT to save changes to original file.**

8. To make changes to a NOTES file you have exported, simply re-open the original PDF proof file, go to File/Import/Notes and import the NOTES file you saved. Make changes and re-export NOTES file keeping the same file name.

9. When complete, attach your NOTES file to a reply e-mail message. Be sure to include your name, the date, and the title of the journal your article will be printed in.

WILEY
Publishers Since 1807

COLOR REPRODUCTION IN YOUR ARTICLE

Color figures were included with the final manuscript files that we received for your article. Because of the high cost of color printing, we can only print figures in color if authors cover the expense.

Please indicate if you would like your figures to be printed in color or black and white. Color images will be reproduced online in Wiley *InterScience* at no charge, whether or not you opt for color printing.

Failure to return this form will result in the publication of your figures in black and white.

JOURNAL Neurourology & Urodynamics VOLUME _____ ISSUE _____

TITLE OF MANUSCRIPT _____

MS. NO. _____ NO. OF COLOR PAGES _____ AUTHOR(S) _____

No. Color Pages	Color Charges	No. Color Pages	Color Charges	No. Color Pages	Color Charges
1	**950**	**5**	**3400**	**9**	**5850**
2	**1450**	**6**	**3900**	**10**	**6350**
3	**1950**	**7**	**4400**	**11**	**6850**
4	**2450**	**8**	**4900**	**12**	**7350**

*****Please contact the Production Editor (swhalen@wiley.com) for a quote if you have more than 12 pages of color*****

☐ Please print my figures in black and white

☐ Please print my figures in color $ _____

***International orders must be paid in currency and drawn on a U.S. bank*

Please check one: ☐ Check enclosed ☐ Bill me ☐ Credit Card

If credit card order, charge to: ☐ American Express ☐ Visa ☐ MasterCard

Credit Card No _____ Signature _____ Exp. Date _____

BILL TO:

Name _____ **Purchase Order No.** _____

Institution _____ Phone _____

Address _____

_____ Fax _____

_____ E-mail _____